Duke Pediatric Fast Facts
Duke Comprehensive Cancer Center
Clinical Trials at Duke Comprehensive Cancer Center
May 13, 2008
| Pediatric Leukemias and Myelproliferative Syndrome | ||||||
| Sponsor | Sponsor ID | Protocol | Phase | Eligibility | Contact | IRB# |
| COG | AALL0331 | ALL, std risk, B-precursor: 3 intensified post-induction CT | III | New diagnosis; 1- <10 yrs | 668-6536 | 7381 |
| Duke-StemCo | 05164 | Leuks/MDS/AA, hi risk: UCBT w/ ALDHbr primed cells | Pilot | 4,5 or 6/6 match unrelated UCB | 668-6536 | 7177 |
| COG | AALL02P2 | ALL, extramedullary relapse: Intensified CT/decreased RT | Pilot | >= 18 yrs < 30 | 668-6432 | 7095 |
| COG | ALL00P2 | T-cel l ALL: BFM +/- Cpd 506U78 | Pilot | New dx | 668-6432 | 3372 |
| BMT CTN | 0501 | Leukemia or MDS, hi risk: Single vs double UCB transplant | III | 3-6 HLA donor match; 2-21 yrs | 668-6536 | 9041 |
| Pediatric Lymphoma | ||||||
| POG | A5971 | Lymphoblastic Lymphoma, newly dx: 4 CT regimens | III | New dx | 668-6432 | 2403 |
| COG | ANHL0131 | NHL (ALCL), adv: Std (VCR) vs VBL consolidation | III | <21 yrs; New dx | 668-6432 | 5695 |
| Pediatric Sarcoma | ||||||
| COG | AOST0221 | Osteosarc, 1st lung mets: Aerosolized GM-CSF/surgery | II | <= 39 yrs | 668-6432 | 7007 |
| COG | ARST0321 | Desmoid tumor: Sulindac/Tamoxifen | II | 4 wk CT window; <= 18 yrs | 668-6432 | 5968 |
| COG | ARST0331 | Rhabdomyosarcoma, newly dx: VAC > VA +/- RT | III | Low risk embryonjal/botryoid/spindle cell; <50 yr | 668-6432 | 6880 |
| COG | ARST0531 | Rhabdomyosarcoma, intrmdt risk: VAC vs VAC alternatiang VI | III | New dx | 668-6536 | 1189 |
| COG | ARST0121 | Rhabdomyosarcoma,1st relapse or progressed: Multiagent CT/Tirapazamine | II | <= 1 prior CT | 668-6432 | 4533 |
| Pediatric Brain Tumor | ||||||
| Duke-NCI | 07174 | Eval CSF Proteome & Angiogenesis Proteins | I/II | Newly diagnosed CNS Tumors | 684-5301 | 0505 |
| COG | ANBL00P3 | Neuroblastoma/ OMA syndrome: CT +/- IV Gammaglobulin | III | 668-6432 | 6436 | |
| PBTC | PBTC-014 | Brainstem glioma, new dx: R115777+RT | I/II | >=3 - <= 21 yrs | 684-5301 | 5927 |
| COG | ACNS0122 | NGGCT: Neoadj CT+/- 2nd look surg > RT | II | 3 to < 25 yrs; New dx | 668-6432 | 5934 |
| PBTC | PBTC-016 | Medullo, glioma or ependymoma, recurr/rfcty: Lapatinib | I/II | <=21 yrs; 3 wk prior CT window | 684-5301 | 6861 |
| St Jude | SJMB03 | Medullo, PNET or ATRT: RT>HiD CT+ auto SCT | II | 3 - 21 yrs; New dx | 684-5301 | 5819 |
| PBTC | PBTC018 | Primary brain, recurr: Phase I CC-5013 | I | <=21 yrs | 684-5301 | 7253 |
| PBTC | PBTC-020 | Primary brain, recurr: AZD2171 | I | <=21 yrs | 668.5364 | 8860 |
| PBTC | PBTC019 | Neoplastic Meningitis: Phase I Topotecan | I | >=3 yrs <= 21 yrs | 684-5301 | 7809 |
| Pediatric Neuroblastoma and Embryonal Tumor | ||||||
| COG | ANBL00P2 | Neuroblastoma < 3 mos: Close observation. | Pilot | No CT/abd surgery | 668-6432 | 3122 |
| COG | AGCT0132 | Extracranial germ cell tumor, low/intermdt risk: Reduced therapy | III | <=21yr | 668-6432 | 7017 |
| Pediatric Wilms' Tumor | ||||||
| COG | AREN0321 | Renal, high risk: CT (dx dependent)/RT | II | <= 30 yrs; new dx | 668-6432 | 1128 |
| Pediatric Phase I and II Clinical Trials | ||||||
| Duke | 07113 | Hi Risk Malig, Myelodysplasia, Severe Anaplastic Anemia: Stem Cell/UCB | I/II | <55. 3/6 or 4/6 donor & 3,4,5, or 6/6 unrelat UCB | 668.1280 | 8717 |